Table 11:

Systematic Reviews of Prostate Cancer Screening Trials

Author, Year	Reviewer Country	Affiliation of Lead Author	Review Sponsor/Funder	Type of Report	Search Period	Outcomes of Interest
Chou et al, 2011 (80) Lin et al, 2011 (85)	United States	Oregon Health and Science University	AHRQ for USPSTF	SR; Update to 2002 and 2008 AHRQ reviews for USPSTF	2002 to July 2011	PC mortality, all-cause mortality, harms of PSA screening, benefits of treating early stage or screen-detected cancers
Djulbegovic et al, 2010 (81)	United States	Urology and Prostate Disease Center, University of Florida	None declared	SR-MA	January 2005 to July 2010	PC mortality, all-cause mortality, PC diagnosis, screening and stage at diagnosis, FP and FN results, harms of screening, QOL, cost-effectiveness
Ilic et al, 2013 (82;86)	Australia	Department of Epidemiology and Preventive Medicine, Monash University Melbourne	Cochrane Collaboration	Update to 2006 and 2010 Cochrane reviews	Up to June 2012	Primary: PC mortality, all-cause mortality. Secondary: incident PC by stage and grade at diagnosis, metastatic disease at follow-up, QoL, harms of screening
Lee et al, 2013 (83)	Korea	Department of Laboratory Medicine and Genetics, Soonchunhyang University	National R&D Program for Cancer Control, Ministry of Health and Welfare	SR of SRs, RCT	Since January 2009	PC mortality, all-cause mortality, PC diagnosis, stage at diagnosis
Lumen et al, 2011 (84)	Belgium	Department of Urology, Ghent University Hospital	None declared	SR	Up to April 2011	PC mortality, all-cause mortality, PC diagnosis, PC incidence, stage and grade

Abbreviations: AHRQ, Agency for Healthcare Research and Quality; FN, false negative; FP, false positive; MA, meta-analysis; PC, prostate cancer; QoL; quality of life; RCT, randomized control trial; SR, systematic review; USPSTF, U.S. Preventive Services Task Force.